Drug Profile

Hepatitis B DNA vaccine - ChronTech Pharma

Alternative Names: ChronVac-B

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inovio Biomedical Corporation; Tripep
Developer ChronTech Pharma; Inovio Pharmaceuticals
Class DNA vaccines; Hepatitis B vaccines
Mechanism of Action Gene transference; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Hepatitis B

Most Recent Events

04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in Sweden (IM, Injection)
01 Sep 2014 Hepatitis B vaccine technology repurchased from Avac Pharma
23 Aug 2013 Hepatitis B DNA vaccine technology sold to Avac Pharma

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com